WO2008046072A3 - Chemical inducers of neurogenesis - Google Patents

Chemical inducers of neurogenesis Download PDF

Info

Publication number
WO2008046072A3
WO2008046072A3 PCT/US2007/081304 US2007081304W WO2008046072A3 WO 2008046072 A3 WO2008046072 A3 WO 2008046072A3 US 2007081304 W US2007081304 W US 2007081304W WO 2008046072 A3 WO2008046072 A3 WO 2008046072A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compounds
neurogenesis
treatment
stem cells
Prior art date
Application number
PCT/US2007/081304
Other languages
French (fr)
Other versions
WO2008046072A2 (en
Inventor
Jay Schneider
Jenny Hsieh
Douglas Frantz
Steven L Mcknight
Joseph M Ready
Original Assignee
Univ Texas
Jay Schneider
Jenny Hsieh
Douglas Frantz
Steven L Mcknight
Joseph M Ready
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Jay Schneider, Jenny Hsieh, Douglas Frantz, Steven L Mcknight, Joseph M Ready filed Critical Univ Texas
Publication of WO2008046072A2 publication Critical patent/WO2008046072A2/en
Publication of WO2008046072A3 publication Critical patent/WO2008046072A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.
PCT/US2007/081304 2006-10-13 2007-10-12 Chemical inducers of neurogenesis WO2008046072A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82933806P 2006-10-13 2006-10-13
US60/829,338 2006-10-13
US95318207P 2007-07-31 2007-07-31
US60/953,182 2007-07-31

Publications (2)

Publication Number Publication Date
WO2008046072A2 WO2008046072A2 (en) 2008-04-17
WO2008046072A3 true WO2008046072A3 (en) 2008-11-27

Family

ID=39283668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/081304 WO2008046072A2 (en) 2006-10-13 2007-10-12 Chemical inducers of neurogenesis

Country Status (1)

Country Link
WO (1) WO2008046072A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101394245B1 (en) * 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 Isoxazole Derivatives and Use thereof
JP5996532B2 (en) * 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Novel heterocyclic compounds as pest control agents
CN103298820B (en) 2010-11-24 2016-08-03 新加坡国立大学 Fluorine boron two pyrrole structure fluorescent dye as neural stem cell probe
ES2592704T3 (en) 2012-07-26 2016-12-01 F. Hoffmann-La Roche Ag Neurogenesis bencisoxazole modulators
BR112015000313A2 (en) 2012-08-06 2017-06-27 Hoffmann La Roche piperazine [1,2-a] indol-1-one and [1,4] diazepino [1,2-a] indol-1-one
CA2882525A1 (en) * 2012-10-01 2014-04-10 F. Hoffman-La Roche Ag Benzimidazoles as cns active agents
CN104812387A (en) 2012-11-20 2015-07-29 霍夫曼-拉罗奇有限公司 Substituted 1,6-naphthyridines
WO2014079850A1 (en) 2012-11-23 2014-05-30 F. Hoffmann-La Roche Ag Substituted heterocyclic derivatives
KR101767329B1 (en) 2013-04-02 2017-08-10 에프. 호프만-라 로슈 아게 Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
MX2015015052A (en) 2013-05-03 2016-02-11 Hoffmann La Roche Neurogenesis-stimulating isoquinoline derivatives.
TWI529171B (en) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 1,7-naphthyridine derivatives
CN104710409B (en) * 2013-12-13 2019-06-04 沈阳中化农药化工研发有限公司 Pyrazolyl pyrimidines aminated compounds and purposes
MX2016008842A (en) 2014-01-20 2016-11-08 Hoffmann La Roche N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders.
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US9745292B2 (en) 2014-03-13 2017-08-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
EP3157917B1 (en) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
US9783510B2 (en) * 2014-08-22 2017-10-10 Vanderbilt University Small molecule mediated transcriptional induction of E-cadherin
US10344023B2 (en) 2014-12-23 2019-07-09 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
CA2971850A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (en) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR
US10738011B2 (en) 2014-12-23 2020-08-11 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
WO2017062581A1 (en) 2015-10-06 2017-04-13 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
CN109563047A (en) 2016-04-07 2019-04-02 蛋白质平衡治疗股份有限公司 Containing silicon atom according to cutting down Kato analog
MA45397A (en) 2016-06-21 2019-04-24 Proteostasis Therapeutics Inc COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR
CA3041676A1 (en) 2016-10-26 2018-05-03 Daniel Parks Pyridazine derivatives, compositions and methods for modulating cftr
WO2018081378A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
EP3532461A1 (en) 2016-10-26 2019-09-04 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
US20200055844A1 (en) 2017-04-28 2020-02-20 Proteostasis Therapeutics, Inc. 4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity
WO2019071078A1 (en) 2017-10-06 2019-04-11 Proteostasis Therapeutics, Inc. Compounds, compositions and methods for increasing cftr activity
CN112457255B (en) * 2017-11-08 2022-08-19 北京嘉林药业股份有限公司 Compounds and their use for treating cancer
EP4183449A1 (en) * 2021-11-17 2023-05-24 Samsara Therapeutics Inc. Autophagy inducing compounds and uses thereof
CN116421605A (en) * 2022-01-04 2023-07-14 中国科学院脑科学与智能技术卓越创新中心 Use of ISX-9 in the treatment of circadian amplitude decline and sleep disorders associated with aging

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418667A2 (en) * 1989-09-22 1991-03-27 BASF Aktiengesellschaft Carboxylic acid amides
WO2003013517A1 (en) * 2001-08-06 2003-02-20 Pharmacia Italia S.P.A. Aminoisoxazole derivatives active as kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418667A2 (en) * 1989-09-22 1991-03-27 BASF Aktiengesellschaft Carboxylic acid amides
WO2003013517A1 (en) * 2001-08-06 2003-02-20 Pharmacia Italia S.P.A. Aminoisoxazole derivatives active as kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEOPOLDO MARCELLO ET AL: "Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D-3 receptors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 49, no. 1, 1 January 2006 (2006-01-01), pages 358 - 365, XP002465112, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
WO2008046072A2 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
WO2008046072A3 (en) Chemical inducers of neurogenesis
IL215912A0 (en) 1,2,4-triazolo[4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
WO2007022506A3 (en) Methods and compositions for treating neurological disease
WO2010006130A3 (en) Pde-10 inhibitors
EP2698166A3 (en) Complement inhibition for improved nerve regeneration
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
CL2009000699A1 (en) Compounds derived from polysubstituted 6-heteroaryl-imidazo [1,2-a] pyridines; pharmaceutical composition; synthesis procedure; intermediate compounds; and its use to treat or prevent neurodegenerative, psychiatric, inflammatory diseases, brain trauma and epilepsy, osteoporosis, cancer, Parkinson's, among others.
WO2014176606A8 (en) Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
WO2011130675A3 (en) Dopaminergic neurons differentiated from pluripotent stem cells and uses of thereof
WO2010014990A3 (en) Method of promoting neurogenesis by modulating secretase activities
GT200800265A (en) PIRIDO (3,2-E) PIRACINAS, ITS USE AS PHOSPHADESTERASE 10 INHIBITORS, AND PROCESSES TO PREPARE THEM.
GB2442915B (en) Perylenequinone derivatives and uses thereof
WO2007047447A3 (en) Diuretic-like compound analogs useful for regulation of central nervous system disorders
AU2006337085A8 (en) Methods of using hedgehog kinase antagonists to inhibit hedgehog signaling and to treat hedgehog mediated disorders
TW200621716A (en) Novel compounds
BRPI0515528A (en) n-methyl hydroxyethylamine useful in treating central nervous system conditions
MX2010001824A (en) Heterocycles as potassium channel modulators.
MX2009006685A (en) Dr6 antagonists and uses thereof in treating neurological disorders.
TW200611701A (en) Novel compounds
WO2006083797A3 (en) Improving and protecting cell therapy for neurological disorders including parkinson's disease
SG157231A1 (en) Substituted p-diaminobenzene derivatives
WO2012044562A3 (en) Pyrazolopyrimidine pde10 inhibitors
MX340807B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
EP2765227A3 (en) Compositions and methods for identifying autism spectrum disorders
WO2012074561A3 (en) Methods and compositions for the treatment of anxiety disorders, including post traumatic stress disorder (ptsd) and related central nervous system (cns) disorders

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07854013

Country of ref document: EP

Kind code of ref document: A2